West Nile Virus Seroprevalence Under Bird Ringers

March 14, 2022 updated by: Chiara de Bellegarde, Leiden University Medical Center

Prevalence of West Nile Virus and Usutu Virus Serum Antibodies in Dutch Bird Ringers

In August 2020, West Nile Virus (WNV) was isolated from a live common whitethroat for the first time in The Netherlands. Follow-up sampling showed that the virus could also be detected in mosquitos from the same location during at least a whole month of sampling. On 15 October 2020, one case of West Nile virus infection has been reported in a man who was likely infected in the Utrecht region. This is the first time that a locally acquired human case of WNV infection has been reported in The Netherlands. Six additional cases have been identified, one of which from the region Arnhem. West Nile virus infection is a mosquito-borne zoonosis. The disease, which has spread across the Northern Hemisphere in the past three decades, is now found on an annual basis in many European countries where the centre of gravity lies in Southern-European countries. Recently, WNV was reported for the first time in Germany. The virus is transmitted among birds through the bite of infected mosquitoes and incidentally infects humans and other mammals, such as horses. Around 80% of human WNV infections are asymptomatic. The most common clinical presentation is West Nile fever but, older people and immunocompromised persons are at higher risk of developing neuro-invasive disorders (West Nile neuroinvasive disease). Currently, there are no prophylaxis or specific treatment against the disease in humans. In addition, Usutu virus (USUV) was detected in The Netherlands in 2016. USUV is another flavivirus, related to WNV, and also capable of infecting humans. Disease associated with USUV infection in humans appears to be milder and only limited number of cases have been identified. During their bird catching activities, bird ringers are intensively exposed to mosquito bites at the natural habitat of the birds and at the same time of the day when mosquitoes are particularly active. The aim of this study is therefore to determine the prevalence of WNV and USUV serum antibodies in bird ringers in The Netherlands.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

162

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Leiden, Netherlands
        • Leiden University Medical Centre (LUMC)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Bird ringers from the Netherlands (about 580 licensed ringers and about 100 additional trainees or helpers)

Description

Inclusion Criteria:

  • Carrying-out bird ringing activities during spring, summer or early autumn 2020 in The Netherlands

Exclusion Criteria:

  • Not willing to participate in this study
  • Using medication interfering with antibodies production
  • Under 18 years of age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The proportion of individuals with neutralising antibodies against WNV by region
Time Frame: One blood sample collected between June and September 2021
One blood sample collected between June and September 2021
The proportion of individuals with neutralising antibodies against USUV by region
Time Frame: One blood sample collected between June and September 2021
One blood sample collected between June and September 2021

Secondary Outcome Measures

Outcome Measure
Time Frame
The proportion of individuals with IgM antibodies against WNV
Time Frame: One blood sample collected between June and September 2021
One blood sample collected between June and September 2021
The proportion of individuals with IgG antibodies against WNV
Time Frame: One blood sample collected between June and September 2021
One blood sample collected between June and September 2021
The proportion of individuals with IgM antibodies against USUV
Time Frame: One blood sample collected between June and September 2021
One blood sample collected between June and September 2021
The proportion of individuals with IgG antibodies against USUV
Time Frame: One blood sample collected between June and September 2021
One blood sample collected between June and September 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Chiara de Bellegarde, LUMC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 28, 2021

Primary Completion (Actual)

September 22, 2021

Study Completion (Actual)

December 14, 2021

Study Registration Dates

First Submitted

February 15, 2022

First Submitted That Met QC Criteria

March 14, 2022

First Posted (Actual)

March 24, 2022

Study Record Updates

Last Update Posted (Actual)

March 24, 2022

Last Update Submitted That Met QC Criteria

March 14, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P20.112

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on West Nile Virus

Subscribe